2 transcripts
SLRN
Earnings call transcript
NASDAQ
2024 Q2
13 Aug 24
the primary endpoint of HiSCR75 and are especially pleased with the compelling response rates in HiSCR90 and HiSCR100 within 12 weeks of treatment
SLRN
Earnings call transcript
NASDAQ
2023 Q2
14 Aug 23
of clinical response due to robust tissue penetration and potent target engagement.
We designed our Phase IIB/III trial with a part A and a Part B. Part
- Prev
- 1
- Next